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doi:10.1016/j.ejvs.2009.12.005Abstract Oral glucose tolerance tests (OGTTs) have detected a pathologic glucose metabo-
lism in up to 60% of patients with acute coronary syndromes. Only one-third of these were
previously diagnosed.
The purpose of this study was to determine the prevalence of abnormal glucose metabolism
among vascular surgery patients.
Methods: Between October 2006 and September 2007, 465 consecutive patients admitted to
the vascular surgery unit were asked to participate in the study; however, 121 declined. Among
the patients included, 68 had previously known diabetes. A total of 276 patients performed an
oral glucose tolerance test (OGTT). We categorised the findings based on fasting and 2-h
plasma glucose levels into four groups: diabetes mellitus, impaired glucose tolerance (IGT),
impaired fasting glucose (IFG) and normal glucose metabolism. Information regarding the
affected vascular bed and relevant medical history was also registered.
Results: Of the 276 patients who underwent OGTT, 66 (24%) had IGT, 23 (8%) had IFG and 33
(12%) had diabetes. As many as 17 of the 33 patients with newly diagnosed diabetes would have
fulfilled the criteria for diagnosis based only on their fasting glucose levels. Including the
patients with previously known diabetes, the prevalence of dysglycaemia was 55% and that
of diabetes 29%.
Conclusions: Total prevalence of dysglycaemia in vascular surgery patients corresponds well to
that of acute coronary syndromes. The prevalence of unknown pathological glucose metabo-
lism was 44% in our OGTT material. The use of fasting glucose as the sole diagnostic tool for
diabetes would have resulted in the correct diagnosis in only half of the patients tested. OGTT
should be considered as a routine investigation in non-diabetic vascular surgery patients. It
remains to be seen whether early diagnosis and treatment of dysglycaemia in this patient
group will influence the surgical treatment and outcome.
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Table 1 WHO-99 criteria for definition of diabetes, IGT,
IFG and normal glucose metabolism.
Plasma glucose
(mmol/l)
Diabetes (DM)
Fasting plasma glucose 7.0
or
2-h Plasma glucosea 11.1
Impaired glucose tolerance (IGT)
Fasting plasma glucose <7.0
and
2-h Plasma glucosea 7.8 and <11.1
Impaired fasting glucose (IFG)
Fasting plasma glucose 6.1e6.9
and (if measured)
2-h Plasma glucosea <7.8
Normal glucose metabolism
Fasting plasma glucose <6.1
2-h Plasma glucosea <7.8
a Venous plasma glucose 2-h after ingestion of 75 g oral
glucose load.
448 M. Astor et al.Patients with diabetes mellitus (DM) have a two- to
threefold increased risk of coronary artery disease (CAD)
than those without diabetes.1e4 The risk of amputation
due to peripheral arterial disease (PAD) is as much as 30
times higher in diabetic individuals than in non-dia-
betics.5,6 The DECODE (Diabetes Epidemiology: Collabo-
rative Analysis of Diagnostic Criteria in Europe) study
demonstrated that patients with DM, impaired glucose
tolerance (IGT) as well as those with newly detected dia-
betes have an increased risk of developing cardiovascular
disease.7,8 These disorders of glucose regulation should be
considered as one continuum as far as macrovascular
disease is concerned.
Among patients with acute coronary syndromes, 20e25%
have known DM. In a study of 168 patients after an acute
myocardial infarction, OGTT revealed a 60% prevalence of
dysglycaemia.9 It was further reported that during a mean
follow-up period of 34 months, 23 out of 39 major cardio-
vascular events occurred in patients with previously undi-
agnosed IGT.
The Edinburgh artery study, a population-based study
from 1999 found that the prevalence of PAD among diabetics
or patients with IGT was considerably higher than among
those with normal glucose metabolism (20% vs. 12%).10 In
contrast to coronary heart disease, little is known about the
frequency of undiagnosed dysglycaemia (here defined as DM,
IGT and impaired fasting glucose (IFG)) and its clinical
implications for vascular surgery patients. Very few studies
have tested patients with PAD using oral glucose tolerance
test (OGTT) to determine the prevalence of abnormal
glucose metabolism.11,12 In Norway, Johansen et al. found
that among 47 patients with PAD the prevalence of formerly
unknown diabetes was 23%, IGT 19% and IFG 15%, yielding
a total of 57% abnormal glucose metabolism.11
The purpose of this study was to investigate the preva-
lence of the various forms of dysglycaemia in vascular
surgery patients using glucose tolerance test.Table 2 Patient characteristics, medical history, smoking and a
All n Z 344 OGTT n Z 27
Normal n Z 1
Age (years) 70 (35e89) 68
Male (%) 74 67
Medical history
CAD n (%) 157 (46) 57 (37)
CVD n (%) 78 (23) 29 (19)
Lung disease n (%) 65 (19) 24 (16)
Kidney failure n (%) 101 (29) 31 (20)
Smoking
Current or former
Smoker n (%)
268 (78) 125 (81)
Vascular bed
Aortica n (%) 67 (19) 31 (20)
Carotid n (%) 51 (15) 26 (17)
IOD n (%) 57 (17) 36 (23)
Infrainguinal n (%) 169 (49) 61 (40)
CAD Z coronary artery disease, CVD Z Cerebrovascular disease. Kid
a Approximately 95% of aortic disease is of aneurism origin.Methods and Materials
BetweenOctober 2006 and September 2007, 465 consecutive
patients admitted to the vascular surgery unit for elective
surgery were asked to participate in the study; however, 121
declined. Informed, written consent was obtained from all
participants. The vascular pathologies were PAD, aneu-
rysmal disease as well as patients with carotid stenosis.
Among the patients included, 68 had previously diag-
nosed diabetes. A total of 276 patients performed an OGTT.
Regional Committee for Medical Research Ethics approved
the protocol (REK vest 14109).ffected vascular bed.
6 Known DM n Z 68
54 Dysglycaemia n Z 122
71 73
81 75
55 (45) 45 (66)
29 (24) 20 (29)
20 (16) 21 (31)
40 (33) 30 (44)
97 (80) 46 (67)
29 (24) 7 (10)
17 (14) 8 (12)
15 (12) 6 (9)
61 (59) 47 (69)
ney failure Z eGFR<60. IOD Z Iliac occlusive disease.
Table 3 Results of OGTT and the metabolic characteristics of known diabetics.
OGTT Known diabetes
Normal IFG IGT Diabetes
Number of patients (n) 154 23 66 33 68
Age (years) 68 67 73 71 73
Fasting glucose (mmol/l) 5.3  0.4 6.3  0.2 5.8  0.5 7.1  1.4 8.6  3.7
2-h glucose (mmol/l) 5.5  1.2 5.7  1.5 9.3  0.8 13.3  4.6 e
Dysglycaemia in Vascular Surgery 449OGTT was performed after a night of fasting, by orally
administering a standard dose of 75 g glucose dissolved in
water. Plasma glucose levels were measured in the fasting
state and 2 h after the glucose load. The glucose levels
were analysed using Modular P (Roche Diagnostics).
According to the World Health Organization (WHO) 99
criteria, we categorised OGTT results into four groups: DM,
IGT, IFG and normal (Table 1).
Information about previous medical history, including
smoking habits and the affected vascular bed was obtained
from the patients’ medical records. The presence of kidney
disease was defined based on estimated glomerular filtra-
tion rates (eGFRs). The distribution of the patients
according to the affected vascular bed is shown in Table 2.
Statistical Analysis
Data are presented as mean and standard deviation (SD).
The chi-square (c2) test was used for inter-group (aortic,
iliac occlusive disease (IOD), infrainguinal and carotid
disease) analysis of glucose levels before and after OGTT.
The software program SPSS for Windows 15.0 (SPSS Inc.,
2006, IL, USA) was used for statistical computations.
Differences were considered statistically significant at the
5% level (p < 0.05).
Results
Patient characteristics are presented in Table 2. The mean
age was 70 (range: 35e89) years and 74% were male. Almost
half of the population had CAD and one out of four had
cerebrovascular disease (CVD). Those with known diabetes
had the highest prevalence of both CAD and CVD (Table 2).Figure 1 Glucose metabolism according to OGTT results
including the known diabetics. IFGZ Impaired fasting glucose,
IGT Z Impaired glucose tolerance, DM Z Diabetes mellitus.As many as 29% had kidney failure, defined as eGFR less
than 60. The diabetics had the highest prevalence of kidney
failure. Most of the population were current or former
cigarette smokers; however, there were fewer smokers
(both present and former) among the diabetics.
The metabolic characteristics are given in Table 3.
Normal glucose levels were observed in 154 (45%) of the
total population after both fasting and 2 h after glucose
load. A total of 276 patients were administered OGTT; of
these, 66 (24%) had IGT, 23 (8%) had IFG and 33 (12%) had
diabetes. Only 17 of the 33 patients with newly diagnosed
diabetes would have fulfilled the criteria for diagnosis
based solely on their fasting glucose levels. Including the
patients with previously known diabetes, the prevalence of
dysglycaemia in the group as a whole was 55% and that of
diabetes 29% (Fig. 1).
Among patients with infrainguinal disease, the preva-
lence of dysglycaemia was 64% (Fig. 2). When examining
the distribution of pathologic glucose metabolism after
OGTT based on the relevant vascular bed, there were no
statistically significant differences (Table 4).
Fasting glucose values were recorded in 120 of the
excluded subjects. In this group, based on fasting glucose
alone, seven patients (6%) were classified as diabetics and
17 (14%) as having IFG.
Discussion
The purpose of this study was to determine the prevalence
of abnormal glucose metabolism among vascular surgery
patients. The prevalence of diabetes in the generalFigure 2 Glucose metabolism in relation to distribution of
vascular disease. The bars indicate frequency of normal
glucose tolerance (Normal), impaired fasting glucose (IFG),
impaired glucose tolerance (IGT), diabetes mellitus detected
after OGTT (New DM) and known diabetes mellitus (Known DM).
The numbers inside bars give the actual number (n) in each
group. IOD Z Iliac occlusive disease.
Table 4 Glucose metabolism in relation to vascular bed
among patients who were administered OGTT.
Vascular bed Normal Dysglycaemia
Aortic (n Z 60) 31 (52%) 29 (48%)
Carotid (n Z 43) 26 (60%) 17 (40%)
IODa (n Z 51) 36 (71%) 15 (29%)
Infrainguinal (n Z 122) 61 (50%) 61 (50%)
The prevalence of dysglycaemia did not differ significantly
between the groups (p Z 0.073).
a Iliac occlusive disease (IOD).
450 M. Astor et al.Norwegian population is estimated at 2.3% with a preva-
lence among the elderly (70e79 years) at almost 8%.13 The
prevalence of IFG and IGT in our country is not known, but
a study from Sweden which included 2595 women over 64
years of age revealed a prevalence of 14.4% for IGT and
6.4% for IFG.14
Our results showed that 55% of patients admitted to the
department of vascular surgery had a pathologic glucose
metabolism. The total frequency of diabetes was 29%,
which is considerably higher than in the general population
in Norway. Patients with infrainguinal disease had the
highest prevalence of both dysglycaemia (64%) and diabetes
(37%). These results correspond well with recent studies
investigating dysglycaemia in patients with both peripheral
and CAD.9,11,12,15
Diabetics have more advanced peripheral artery disease
as compared to non-diabetics. Both micro- and macro-
vascular complications associated with diabetes may
develop well before diabetes is established, that is, among
those with non-diabetic hyperglycaemia (IFG and IGT).16 In
addition, long-term cardiovascular outcome is poorer in
vascular surgery patients with IGT, as shown in a recent
Dutch study.17
Furthermore, as atherosclerosis is a systemic disease,
high prevalence of both coronary and cerebrovascular
disease is to be expected, as demonstrated by our results
(Table 2). This is in accordance with the previous finding
that patients with CAD have a similarly high prevalence of
dysglycaemia.9
The use of fasting glucose as the sole diagnostic tool for
diabetes would have resulted in the correct diagnosis in
only half of the patients examined. A high prevalence of
dysglycaemia was found irrespective of distribution of
vascular pathology (Table 4). This highlights the impor-
tance of administering OGTT to all vascular surgery
patients with fasting glucose below 7.0 mmol l1. Patients
with fasting glucose above or equal to 7.0 mmol l1
(measured on two occasions, or once if experiencing
hyperglycaemic symptoms) have diabetes and should not
perform an OGTT.
A potential confounder in this study was the high number
of excluded patients. However, mean fasting glucose
(5.6 mmol l1) for those excluded was very similar to the
value (5.7 mmol l1) for the participants. Since OGTT was
not administered to the non-participants, it can be
assumed, based on the results of those tested, that dys-
glycaemia has been missed in roughly half of the non-
participants. The prevalence of diabetes based on fasting
glucose only, was the same in both groups (6%). Wetherefore believe that the high number of non-participants
does not pose a significant threat to the validity of our
results.
Our results show a 55% prevalence of dysglycaemia
among vascular surgery patients admitted for elective
surgery. It remains to be seen whether early diagnosis and
treatment of dysglycaemia in this patient group will influ-
ence the surgical treatment and outcome.
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